Behavioral Activation Plus Low Vision Rehab Beneficial in AMD

Share this content:
Behavioral Activation Plus Low Vision Rehab Beneficial in AMD
Behavioral Activation Plus Low Vision Rehab Beneficial in AMD

MONDAY, March 20, 2017 (HealthDay News) -- Behavioral activation (BA) plus low vision rehabilitation with an occupational therapist (OT-LVR) is more effective than conventional low vision optometry services for patients with age-related macular degeneration (AMD), according to a study published in the March issue of Investigative Ophthalmology & Visual Science.

Ashley D. Deemer, O.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a randomized clinical trial involving 188 AMD patients with subsyndromal depressive symptoms. Participants had two outpatient low vision rehabilitation optometry visits and were randomly allocated to in-home BA + OT-LVR, which aimed to increase adaptive behaviors and achieve valued goals, or supportive therapy (ST), which is a nondirective, psychological treatment that provides emotional support. The active inventory was used to assess functional vision at baseline and four months in terms of goals and corresponding tasks.

The researchers found that both the BA + OT-LVR and ST groups had improvement in functional vision measures at the goal level. Compared with ST patients, BA + OT-LVR patients showed more improvement in reading, inside-the-home tasks, and outside-the-home tasks, at the task level. Subjects with a visual acuity of ≥20/70 had the greatest effects in the BA + OT-LVR group.

"BA + OT-LVR services, provided by an OT in the patient's home following conventional low vision optometry services, are more effective than conventional optometric low vision services alone for those with mild visual impairment," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »